266 related articles for article (PubMed ID: 19951112)
1. Voriconazole pharmacokinetics and pharmacodynamics in children.
Neely M; Rushing T; Kovacs A; Jelliffe R; Hoffman J
Clin Infect Dis; 2010 Jan; 50(1):27-36. PubMed ID: 19951112
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
5. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
[TBL] [Abstract][Full Text] [Related]
6. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.
Mohammedi I; Piens MA; Padoin C; Robert D
Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225
[No Abstract] [Full Text] [Related]
11. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients.
Mori M; Fukushima K; Miharu M; Goto H; Yoshida M; Shoji S
J Infect Chemother; 2013 Feb; 19(1):174-9. PubMed ID: 22714745
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
15. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.
Peng LW; Lien YH
Am J Kidney Dis; 2005 Jan; 45(1):162-6. PubMed ID: 15696456
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
19. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.
Friberg LE; Ravva P; Karlsson MO; Liu P
Antimicrob Agents Chemother; 2012 Jun; 56(6):3032-42. PubMed ID: 22430956
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
Walsh TJ; Driscoll T; Milligan PA; Wood ND; Schlamm H; Groll AH; Jafri H; Arrieta AC; Klein NJ; Lutsar I
Antimicrob Agents Chemother; 2010 Oct; 54(10):4116-23. PubMed ID: 20660687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
